Next-generation CelMods, like iberdomide, represent a significant therapeutic advance by actively killing myeloma cells. This is a direct contrast to the previous IMiD class of drugs, which only induced growth arrest. This shift in mechanism is driven by higher potency in binding cereblon, leading to more rapid degradation of cancer targets.
In a crowded multiple myeloma treatment landscape with options like CAR-T and bispecifics, patient preference often leans toward the least intensive regimen. Clinicians must present a menu of viable options, allowing patients to select a therapy that aligns with their personal circumstances and quality-of-life goals, knowing more intensive options remain available later.
A key advantage of the new CelMod iberdomide is its significantly cleaner safety profile, specifically a lower rate of severe non-hematologic side effects like diarrhea and confusion. This improved tolerability is a critical factor for treatment selection and patient adherence in a chronic condition like multiple myeloma, making the drug much easier for patients to take.